TheraRadar
← Back
Data updated: Mar 29, 2026

EDENBRIDGE PHARMS

Cardiovascular
Specialty

EDENBRIDGE PHARMS is a specialty pharmaceutical company focused on Cardiovascular. Key products include ZUBSOLV.

2013
Since
12
Drugs
-
Trials
62
Approved (2yr)

Key Drugs

YARGESA
miglustat
Rare Disease
Glucosylceramide synthase 1 indications · 2020
ZUBSOLV
buprenorphine hydrochloride
Kappa-opioid receptor 1 indications · 2013

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-24
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-24
Labeling
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE 2026-01-21
DILTIAZEM HYDROCHLORIDE 2026-01-18
Labeling
LOPERAMIDE HYDROCHLORIDE 2025-12-29
ZUBSOLV 2025-12-22
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 100%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Cardiovascular
Merck big-pharma
Cardiovascular
Baxter specialty
Cardiovascular
Johnson & Johnson big-pharma
Cardiovascular
Bayer big-pharma
Cardiovascular